Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT07510100 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)

Sponsor

Nanjing IASO Biotechnology Co., Ltd.